Autism and fragile X syndrome

Seminars in Neurology

Volumn 34, Issue 3, 2014, Pages 258-265

  Yu, Timothy W ^a   Berry Kravis, Elizabeth ^b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

autism spectrum disorder; fragile X mental retardation 1 geneintellectual disability; fragile X mental retardation protein; fragile X syndrome

Indexed keywords

ALLELE; ARTICLE; AUTISM; COGNITIVE DEFECT; EXOME; FRAGILE X SYNDROME; HUMAN; INTELLECTUAL IMPAIRMENT; NERVE CELL PLASTICITY; NEUROBIOLOGY; PHENOTYPE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SYNAPSE; ANIMAL; DISEASE MODEL; GENETIC PREDISPOSITION; GENETICS;

ANIMALS; AUTISTIC DISORDER; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; FRAGILE X SYNDROME; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PHENOTYPE;

EID: 84922671834     PISSN: 02718235     EISSN: 10989021     Source Type: Journal    
DOI: 10.1055/s-0034-1386764     Document Type: Article

References (96)

1. Baio J. Prevalence of autism spectrum disorder among children aged 8 years - autism and developmental disabilities monitoring network, 11 sites, United States, 2010. MMWR Surveill Summ: 2014; 63 2 1 21
2. Kim Y. S., Leventhal B. L., Koh Y-J., et al. Prevalence of autism spectrum disorders in a total population sample. Am J Psychiatry: 2011; 168 9 904 912
3. Werling D. M., Geschwind D. H. Sex differences in autism spectrum disorders. Curr Opin Neurol: 2013; 26 2 146 153
4. Bauman M. L. Medical comorbidities in autism: challenges to diagnosis and treatment. Neurotherapeutics: 2010; 7 3 320 327
5. Doshi-Velez F., Ge Y., Kohane I. Comorbidity clusters in autism spectrum disorders: an electronic health record time-series analysis. Pediatrics: 2014; 133 1 e54 e63
6. Lavelle T. A., Weinstein M. C., Newhouse J. P., Munir K., Kuhlthau K. A., Prosser L. A. Economic burden of childhood autism spectrum disorders. Pediatrics: 2014; 133 3 e520 e529
7. Rossignol D. A., Frye R. E. Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis. Mol Psychiatry: 2012; 17 3 290 314
8. Butler M. G., Dasouki M. J., Zhou X-P., et al. Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J Med Genet: 2005; 42 4 318 321
9. Geschwind D. H. Advances in autism. Annu Rev Med: 2009; 60 367 380
10. Jeste S. S. The neurology of autism spectrum disorders. Curr Opin Neurol: 2011; 24 2 132 139
11. Amaral D. G., Schumann C. M., Nordahl C. W. Neuroanatomy of autism. Trends Neurosci: 2008; 31 3 137 145
12. Folstein S., Rutter M. Genetic influences and infantile autism. Nature: 1977; 265 5596 726 728
13. Steffenburg S., Gillberg C., Hellgren L., et al. A twin study of autism in Denmark, Finland, Iceland, Norway and Sweden. J Child Psychol Psychiatry: 1989; 30 3 405 416
14. Bailey A., Le Couteur A., Gottesman I., et al. Autism as a strongly genetic disorder: evidence from a British twin study. Psychol Med: 1995; 25 1 63 77
15. Lichtenstein P., Carlström E., Råstam M., Gillberg C., Anckarsäter H. The genetics of autism spectrum disorders and related neuropsychiatric disorders in childhood. Am J Psychiatry: 2010; 167 11 1357 1363
16. Ronald A., Happé F., Plomin R. Genetic research into autism. Science: 2006; 311 5763 952, author reply 952
17. Hallmayer J., Cleveland S., Torres A., et al. Genetic heritability and shared environmental factors among twin pairs with autism. Arch Gen Psychiatry: 2011; 68 11 1095 1102
18. Constantino J. N., Todorov A., Hilton C., et al. Autism recurrence in half siblings: strong support for genetic mechanisms of transmission in ASD. Mol Psychiatry: 2013; 18 2 137 138
19. Sandin S., Lichtenstein P., Kuja-Halkola R., Larsson H., Hultman C. M., Reichenberg A. The familial risk of autism. JAMA: 2014; 311 17 1770 1777
20. Cohen D., Pichard N., Tordjman S., et al. Specific genetic disorders and autism: clinical contribution towards their identification. J Autism Dev Disord: 2005; 35 1 103 116
21. Betancur C. Etiological heterogeneity in autism spectrum disorders: more than 100 genetic and genomic disorders and still counting. Brain Res: 2011; 1380 42 77
22. Wandstrat A. E., Leana-Cox J., Jenkins L., Schwartz S. Molecular cytogenetic evidence for a common breakpoint in the largest inverted duplications of chromosome 15. Am J Hum Genet: 1998; 62 4 925 936
23. Goizet C., Excoffier E., Taine L., et al. Case with autistic syndrome and chromosome 22q13.3 deletion detected by FISH. Am J Med Genet: 2000; 96 6 839 844
24. Prasad C., Prasad A. N., Chodirker B. N., et al. Genetic evaluation of pervasive developmental disorders: the terminal 22q13 deletion syndrome may represent a recognizable phenotype. Clin Genet: 2000; 57 2 103 109
25. Jamain S., Quach H., Betancur C., et al. Paris Autism Research International Sibpair Study. Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat Genet: 2003; 34 1 27 29
26. Kim H-G, Kishikawa S., Higgins A. W., et al. Disruption of neurexin 1 associated with autism spectrum disorder. Am J Hum Genet: 2008; 82 1 199 207
27. Durand C. M., Betancur C., Boeckers T. M., et al. Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat Genet: 2007; 39 1 25 27
28. Berkel S., Marshall C. R., Weiss B., et al. Mutations in the SHANK2 synaptic scaffolding gene in autism spectrum disorder and mental retardation. Nat Genet: 2010; 42 6 489 491
29. Lai C. SL, Fisher S. E., Hurst J. A., Vargha-Khadem F., Monaco A. P. A forkhead-domain gene is mutated in a severe speech and language disorder. Nature: 2001; 413 6855 519 523
30. Weiss L. A., Shen Y., Korn J. M., et al. Autism Consortium. Association between microdeletion and microduplication at 16p11.2 and autism. N Engl J Med: 2008; 358 7 667 675
31. Christian S. L., Brune C. W., Sudi J., et al. Novel submicroscopic chromosomal abnormalities detected in autism spectrum disorder. Biol Psychiatry: 2008; 63 12 1111 1117
32. Gilman S. R., Iossifov I., Levy D., Ronemus M., Wigler M., Vitkup D. Rare de novo variants associated with autism implicate a large functional network of genes involved in formation and function of synapses. Neuron: 2011; 70 5 898 907
33. Marshall C. R., Noor A., Vincent J. B., et al. Structural variation of chromosomes in autism spectrum disorder. Am J Hum Genet: 2008; 82 2 477 488
34. Sebat J., Lakshmi B., Malhotra D., et al. Strong association of de novo copy number mutations with autism. Science: 2007; 316 5823 445 449
35. Shen Y., Dies K. A., Holm I. A., et al. Autism Consortium Clinical Genetics/DNA Diagnostics Collaboration. Clinical genetic testing for patients with autism spectrum disorders. Pediatrics: 2010; 125 4 e727 e735
36. Sanders S. J., Ercan-Sencicek A. G., Hus V., et al. Multiple recurrent de novo CNVs, including duplications of the 7q11.23 Williams syndrome region, are strongly associated with autism. Neuron: 2011; 70 5 863 885
37. Levy D., Ronemus M., Yamrom B., et al. Rare de novo and transmitted copy-number variation in autistic spectrum disorders. Neuron: 2011; 70 5 886 897
38. Pinto D., Pagnamenta A. T., Klei L., et al. Functional impact of global rare copy number variation in autism spectrum disorders. Nature: 2010; 466 7304 368 372
39. Glessner J. T., Wang K., Cai G., et al. Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature: 2009; 459 7246 569 573
40. Talkowski M. E., Rosenfeld J. A., Blumenthal I., et al. Sequencing chromosomal abnormalities reveals neurodevelopmental loci that confer risk across diagnostic boundaries. Cell: 2012; 149 3 525 537
41. Konyukh M., Delorme R., Chaste P., et al. Variations of the candidate SEZ6L2 gene on Chromosome 16p11.2 in patients with autism spectrum disorders and in human populations. PLoS ONE: 2011; 6 3 e17289
42. Golzio C., Willer J., Talkowski M. E., et al. KCTD13 is a major driver of mirrored neuroanatomical phenotypes of the 16p11.2 copy number variant. Nature: 2012; 485 7398 363 367
43. Girirajan S., Rosenfeld J. A., Cooper G. M., et al. A recurrent 16p12.1 microdeletion supports a two-hit model for severe developmental delay. Nat Genet: 2010; 42 3 203 209
44. Girirajan S., Rosenfeld J. A., Coe B. P., et al. Phenotypic heterogeneity of genomic disorders and rare copy-number variants. N Engl J Med: 2012; 367 14 1321 1331
45. O'Roak B. J., Vives L., Girirajan S., et al. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature: 2012; 485 7397 246 250
46. Sanders S. J., Murtha M. T., Gupta A. R., et al. De novo mutations revealed by whole-exome sequencing are strongly associated with autism. Nature: 2012; 485 7397 237 241
47. Iossifov I., Ronemus M., Levy D., et al. De novo gene disruptions in children on the autistic spectrum. Neuron: 2012; 74 2 285 299
48. O'Roak B. J., Vives L., Fu W., et al. Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. Science: 2012; 338 6114 1619 1622
49. Buxbaum J. D., Daly M. J., Devlin B., Lehner T., Roeder K., State M. W. Autism Sequencing Consortium The autism sequencing consortium: large-scale, high-throughput sequencing in autism spectrum disorders. Neuron: 2012; 76 6 1052 1056
50. Chahrour M. H., Yu T. W., Lim E. T., et al. ARRA Autism Sequencing Collaboration. Whole-exome sequencing and homozygosity analysis implicate depolarization-regulated neuronal genes in autism. PLoS Genet: 2012; 8 4 e1002635
51. Yu T. W., Chahrour M. H., Coulter M. E., et al. Using whole-exome sequencing to identify inherited causes of autism. Neuron: 2013; 77 2 259 273
52. Lim E. T., Raychaudhuri S., Sanders S. J., et al. NHLBI Exome Sequencing Project. Rare complete knockouts in humans: population distribution and significant role in autism spectrum disorders. Neuron: 2013; 77 2 235 242
53. Basel-Vanagaite L., Dallapiccola B., Ramirez-Solis R., et al. Deficiency for the ubiquitin ligase UBE3B in a blepharophimosis-ptosis-intellectual-disability syndrome. Am J Hum Genet: 2012; 91 6 998 1010
54. Novarino G., El-Fishawy P., Kayserili H., et al. Mutations in BCKD-kinase lead to a potentially treatable form of autism with epilepsy. Science: 2012; 338 6105 394 397
55. Willsey A. J., Sanders S. J., Li M., et al. Coexpression networks implicate human midfetal deep cortical projection neurons in the pathogenesis of autism. Cell: 2013; 155 5 997 1007
56. Helsmoortel C., Vulto-van Silfhout A. T., Coe B. P., et al. A SWI/SNF-related autism syndrome caused by de novo mutations in ADNP. Nat Genet: 2014; 46 4 380 384
57. Voineagu I., Wang X., Johnston P., et al. Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature: 2011; 474 7351 380 384
58. Parikshak N. N., Luo R., Zhang A., et al. Integrative functional genomic analyses implicate specific molecular pathways and circuits in autism. Cell: 2013; 155 5 1008 1021
59. Neale B. M., Kou Y., Liu L., et al. Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nature: 2012; 485 7397 242 245
60. Uddin M., Tammimies K., Pellecchia G., et al. Brain-expressed exons under purifying selection are enriched for de novo mutations in autism spectrum disorder. Nat Genet: 2014;;46(7):742-747.
61. Pinto D., Delaby E., Merico D., et al. Convergence of genes and cellular pathways dysregulated in autism spectrum disorders. Am J Hum Genet: 2014; 94 5 677 694
62. Luo R., Sanders S. J., Tian Y., et al. Genome-wide transcriptome profiling reveals the functional impact of rare de novo and recurrent CNVs in autism spectrum disorders. Am J Hum Genet: 2012; 91 1 38 55
63. Kelleher R. J. III, Geigenmüller U., Hovhannisyan H., et al. High-throughput sequencing of mGluR signaling pathway genes reveals enrichment of rare variants in autism. PLoS ONE: 2012; 7 4 e35003
64. Steinberg J., Webber C. The roles of FMRP-regulated genes in autism spectrum disorder: single- and multiple-hit genetic etiologies. Am J Hum Genet: 2013; 93 5 825 839
65. Coffee B., Keith K., Albizua I., et al. Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA. Am J Hum Genet: 2009; 85 4 503 514
66. Willemsen R., Levenga J., Oostra B. A. CGG repeat in the FMR1 gene: size matters. Clin Genet: 2011; 80 3 214 225
67. Seltzer M. M., Baker M. W., Hong J., Maenner M., Greenberg J., Mandel D. Prevalence of CGG expansions of the FMR1 gene in a US population-based sample. Am J Med Genet B Neuropsychiatr Genet: 2012; 159B 5 589 597
68. Tassone F., Iong K. P., Tong T-H., et al. FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States. Genome Med: 2012; 4 12 100
69. Ladd P. D., Smith L. E., Rabaia N. A., et al. An antisense transcript spanning the CGG repeat region of FMR1 is upregulated in premutation carriers but silenced in full mutation individuals. Hum Mol Genet: 2007; 16 24 3174 3187
70. Iliff A. J., Renoux A. J., Krans A., Usdin K., Sutton M. A., Todd P. K. Impaired activity-dependent FMRP translation and enhanced mGluR-dependent LTD in Fragile X premutation mice. Hum Mol Genet: 2013; 22 6 1180 1192
71. Berry-Kravis E., Abrams L., Coffey S. M., et al. Fragile X-associated tremor/ataxia syndrome: clinical features, genetics, and testing guidelines. Mov Disord: 2007; 22 14 2018 2030, quiz 2140
72. Berry-Kravis E., Grossman A. W., Crnic L. S., et al. Understanding fragile X syndrome. Curr Pediatr: 2002; 12 316 324
73. Kidd S. L., Lachiewicz A., Barbouth D., et al. Fragile X syndrome: a review of associated medical problems. J Pediatr: 2014;; In press
74. Berry-Kravis E., Sumis A., Hervey C., Mathur S. Clinic-based retrospective analysis of psychopharmacology for behavior in fragile x syndrome. Int J Pediatr: 2012; 2012 843016
75. Loesch D. Z., Huggins R. M., Hagerman R. J. Phenotypic variation and FMRP levels in fragile X. Ment Retard Dev Disabil Res Rev: 2004; 10 1 31 41
76. Wang L. W., Berry-Kravis E., Hagerman R. J. Fragile X: leading the way for targeted treatments in autism. Neurotherapeutics: 2010; 7 3 264 274
77. Talisa V. B., Boyle L., Crafa D., Kaufmann W. E. Autism and anxiety in males with fragile X syndrome: an exploratory analysis of neurobehavioral profiles from a parent survey. Am J Med Genet A: 2014; 164A 5 1198 1203
78. Bailey D. B. Jr, Raspa M., Bishop E., Olmsted M., Mallya U. G., Berry-Kravis E. Medication utilization for targeted symptoms in children and adults with fragile X syndrome: US survey. J Dev Behav Pediatr: 2012; 33 1 62 69
79. Berry-Kravis E., Knox A., Hervey C. Targeted treatments for fragile X syndrome. J Neurodev Disord: 2011; 3 3 193 210
80. Huber K. M., Gallagher S. M., Warren S. T., Bear M. F. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci U S A: 2002; 99 11 7746 7750
81. Deng P-Y, Rotman Z., Blundon J. A., et al. FMRP regulates neurotransmitter release and synaptic information transmission by modulating action potential duration via BK channels. Neuron: 2013; 77 4 696 711
82. Berry-Kravis E. Mechanism-based treatments in neurodevelopmental disorders: fragile X syndrome. Pediatr Neurol: 2014; 50 4 297 302
83. Grossman A. W., Aldridge G. M., Weiler I. J., Greenough W. T. Local protein synthesis and spine morphogenesis: Fragile X syndrome and beyond. J Neurosci: 2006; 26 27 7151 7155
84. Bilousova T. V., Dansie L., Ngo M., et al. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J Med Genet: 2009; 46 2 94 102
85. Henderson C., Wijetunge L., Kinoshita M. N., et al. Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Sci Transl Med: 2012; 4 152 152ra128
86. Yuskaitis C. J., Mines M. A., King M. K., Sweatt J. D., Miller C. A., Jope R. S. Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome. Biochem Pharmacol: 2010; 79 4 632 646
87. McBride S. MJ, Choi C. H., Wang Y., et al. Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron: 2005; 45 5 753 764
88. Michalon A., Sidorov M., Ballard T. M., et al. Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron: 2012; 74 1 49 56
89. Berry-Kravis E., Sumis A., Hervey C., et al. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Dev Behav Pediatr: 2008; 29 4 293 302
90. Leigh M. JS, Nguyen D. V., Mu Y., et al. A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome. J Dev Behav Pediatr: 2013; 34 3 147 155
91. Berry-Kravis E. M., Hessl D., Rathmell B., et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci Transl Med: 2012; 4)152):152 ra127
92. Erickson C. A., Wink L. K., Ray B., et al. Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome. Psychopharmacology (Berl): 2013; 228 1 75 84
93. Berry-Kravis E., Hessl D., Coffey S., et al. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet: 2009; 46 4 266 271
94. Jacquemont S., Curie A., des Portes V., et al. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med: 2011; 3 64 64ra1
95. Berry-Kravis E., Hessl D., Abbeduto L., Reiss A. L., Beckel-Mitchener A., Urv T. K. Outcome Measures Working Groups Outcome measures for clinical trials in fragile X syndrome. J Dev Behav Pediatr: 2013; 34 7 508 522
96. Waltes R., Duketis E., Knapp M., et al. Common variants in genes of the postsynaptic FMRP signalling pathway are risk factors for autism spectrum disorders. Hum Genet: 2014; 133 6 781 792